| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
(Address of principal executive offices, including zip code) |
| 27 Oct 2026 | FORM DEFA14A |
| 22 Oct 2026 |
Proxy statement: annual meeting on December 10, 2026
CEO pay $845K, down 4.4% · say-on-pay vote |
| 22 Sep 2026 | FORM 10-K |
| 22 Sep 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 |
Form 4: Disbrow Joshua R., Director
Received 30,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Pyszczymuka Greg, Chief Commercial Officer
Received 20,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Disbrow Jarrett, Chief Business Officer
Received 15,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Selhorn Ryan J, Chief Financial Officer
Received 25,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Liu Vivian H, Director
Received 10,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Jain Abhinav, Director
Received 10,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Dockery Carl, Director
Received 10,000 shares as a grant or award |
| 30 Jul 2026 |
Form 4: Donofrio John Jr., Director
Received 10,000 shares as a grant or award |
| 25 Jun 2026 |
8-K: Termination of a Material Definitive Agreement
On June 23, 2026, Aytu BioPharma, Inc. (the “Company”) and Lannett Company, Inc. (together with its affiliates, “Lannett”) mutually agreed to terminate, effective as of June 23, 2026, that certain exclusive license agreement entered into... |
| 13 May 2026 | FORM 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates |
| 02 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”) |
| 17 Feb 2026 | SCHEDULE 13G/A |
Loading...